☰

Steven P. Angus, Ph.D. - Publications

Affiliations: 
2003 University of Cincinnati, Cincinnati, OH 
Area:
Cell Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, et al. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. Plos One. 16: e0252048. PMID 34264955 DOI: 10.1371/journal.pone.0252048  0.336
2021 Mehta GA, Angus SP, Khella CA, Tong K, Khanna P, Dixon SAH, Verzi MP, Johnson GL, Gatza ML. SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. Npj Breast Cancer. 7: 40. PMID 33837205 DOI: 10.1038/s41523-021-00248-2  0.367
2020 Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK. Molecular Cancer Therapeutics. PMID 32847978 DOI: 10.1158/1535-7163.Mct-19-1017  0.382
2019 Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Targeted Oncology. PMID 31429028 DOI: 10.1007/S11523-019-00662-4  0.39
2019 Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Molecular Cancer Research : McR. PMID 31000582 DOI: 10.1158/1541-7786.Mcr-18-1121  0.461
2019 Smithberger E, Shelton AK, Butler MK, Flores AR, Bash RE, Angus SP, Sciaky N, Dhruv HD, Johnson GL, Berens ME, Furnari FB, Miller CR. Abstract 3019: Dynamic kinome profiling of EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy Cancer Research. 79: 3019-3019. DOI: 10.1158/1538-7445.Sabcs18-3019  0.421
2019 Shih C, Blakeley J, Clapp DW, Armstrong AE, Wolters P, Dombi E, Cutter G, Ullrich NJ, Allen J, Packer R, Goldman S, Gutmann DH, Plotkin S, Rosser T, Robertson K, ... ... Angus S, et al. Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct233  0.36
2019 Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, East M, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Ryan Miller C. DRES-13. DUAL KINASE INHIBITION TO COMBAT EGFR-INHIBITOR RESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 21: vi74-vi74. DOI: 10.1093/Neuonc/Noz175.300  0.455
2018 Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, ... ... Angus SP, et al. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas. Human Molecular Genetics. PMID 30335132 DOI: 10.1093/Hmg/Ddy361  0.327
2018 Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, et al. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncology. PMID 29982664 DOI: 10.1093/Neuonc/Noy046  0.42
2018 Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM. Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer. Oncotarget. 9: 15480-15497. PMID 29643987 DOI: 10.18632/Oncotarget.24337  0.373
2018 Smithberger E, Shelton A, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-08. DYNAMIC KINOME PROFILING OF GENETICALLY-DEFINED, EGFRvIII-DRIVEN MURINE ASTROCYTE MODELS OF GLIOBLASTOMA REVEALS TARGETS FOR DUAL KINASE INHIBITOR THERAPY Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.315  0.333
2018 Shelton A, Smithberger E, Butler M, Flores A, Bash R, Angus S, Sciaky N, Dhruv H, Johnson G, Berens M, Furnari F, Miller R. DRES-07. DEFINING THE MECHANISMS OF ACQUIRED RESISTANCE TO TYROSINE KINASE INHIBITORS IN EGFR-DRIVEN GLIOBLASTOMAS USING INTEGRATED KINOME AND TRANSCRIPTOME PROFILING Neuro-Oncology. 20: vi77-vi77. DOI: 10.1093/Neuonc/Noy148.314  0.337
2018 Beauchamp R, Erdin S, Angus S, Stuhlmiller T, Oblinger J, Jordan J, Haggarty SJ, R. Plotkin S, Chang L, L. Johnson G, F. Gusella J, Ramesh V. CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA Neuro-Oncology. 20: vi52-vi52. DOI: 10.1093/Neuonc/Noy148.208  0.322
2017 Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr D, Karagoz K, Sciaky N, Gatza M, Sharpless NE, Johnson GL, Bear JE. New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging. Cancer Research. PMID 29180473 DOI: 10.1158/0008-5472.Can-17-1653  0.428
2017 Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition. Journal of the American Heart Association. 6. PMID 29051215 DOI: 10.1161/Jaha.117.006635  0.447
2017 Angus SP, Zawistowski JS, Johnson GL. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. Annual Review of Pharmacology and Toxicology. PMID 28934561 DOI: 10.1146/Annurev-Pharmtox-010617-052954  0.482
2017 McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AE, et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-Oncology. PMID 28379424 DOI: 10.1093/Neuonc/Nox044  0.408
2017 Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, et al. Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discovery. PMID 28108460 DOI: 10.1158/2159-8290.Cd-16-0653  0.466
2017 Angus SP, Stuhlmiller T, Sciaky N, Chen X, Naim R, Tanioka M, Gallagher KK, Forero A, Krop IE, Thompson AM, Murthy RK, He X, Perou CM, Earp S, Carey LA, et al. TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). Journal of Clinical Oncology. 35: 1027-1027. DOI: 10.1200/Jco.2017.35.15_Suppl.1027  0.313
2016 Stuhlmiller TJ, Miller SM, Zawistowski JS, Duncan JS, Angus SP, Granger DA, Reuther RA, Collins KAL, Shawn GM, Kuan P, Chen X, Sciaky N, Johnson GL. Abstract B25: BET bromodomain inhibition targets adaptive responses to lapatinib in HER2-positive breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B25  0.476
2016 Zawistowski JS, Miller SM, Goulet DR, Stuhlmiller TJ, Singh D, Sciaky N, Velarde SH, Angus SP, Johnson GL. Abstract B24: Triple-negative breast cancer adaptive response to MEK inhibition is regulated by the induction of super-enhancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B24  0.475
2016 Brighton HE, Angus S, Bo T, Darr D, Sharpless NE, Johnson GL, Bear JE. Abstract 4382: Intravital imaging of endogenous BRAFV600E melanoma reveals plasticity of tumor response and resistance to trametinib over time Cancer Research. 76: 4382-4382. DOI: 10.1158/1538-7445.Am2016-4382  0.427
2015 Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Reports. 11: 390-404. PMID 25865888 DOI: 10.1016/J.Celrep.2015.03.037  0.457
2015 Adegbola A, Musante L, Callewaert B, Maciel P, Hu H, Isidor B, Picker-Minh S, Le Caignec C, Delle Chiaie B, Vanakker O, Menten B, D'heedene A, Bockaert N, Roelens F, Decaestecker K, ... ... Angus SP, et al. Redefining the MED13L syndrome. European Journal of Human Genetics : Ejhg. PMID 25758992 DOI: 10.1038/Ejhg.2015.26  0.348
2015 Park SI, Lin CP, Dittmer DP, Angus SP, Wang GG, Fedoriw YD, Darr DB, Roth DP, Sharpless NE, Damania B. Alisertib, an Aurora a Kinase Inhibitor, Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma Cells Blood. 126: 1551-1551. DOI: 10.1182/Blood.V126.23.1551.1551  0.507
2014 Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2516-22. PMID 24664307 DOI: 10.1158/1078-0432.Ccr-13-1081  0.442
2014 Angus SP, Stuhlmiller TJ, Reuther R, Pham TT, Granger DA, Darr DB, Jordan JL, Moschos SJ, Johnson GL, Sharpless NE. Abstract 4761: Defining the adaptive kinome response to BRAF and MEK inhibition in melanoma Cancer Research. 74: 4761-4761. DOI: 10.1158/1538-7445.Am2014-4761  0.461
2013 Pham TT, Angus SP, Johnson GL. MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes & Cancer. 4: 419-26. PMID 24386504 DOI: 10.1177/1947601913513950  0.453
2013 Shats I, Gatza ML, Liu B, Angus SP, You L, Nevins JR. FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. Cancer Research. 73: 6056-67. PMID 23966291 DOI: 10.1158/0008-5472.Can-13-0453  0.515
2013 Liu B, Shats I, Angus SP, Gatza ML, Nevins JR. Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression. The Journal of Biological Chemistry. 288: 24581-9. PMID 23853115 DOI: 10.1074/Jbc.M113.467506  0.442
2012 Angus SP, Nevins JR. A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest. Oncogene. 31: 4709-17. PMID 22249253 DOI: 10.1038/Onc.2011.622  0.501
2009 Stengel KR, Thangavel C, Solomon DA, Angus SP, Zheng Y, Knudsen ES. Retinoblastoma/p107/p130 pocket proteins: protein dynamics and interactions with target gene promoters. The Journal of Biological Chemistry. 284: 19265-71. PMID 19279001 DOI: 10.1074/jbc.M808740200  0.582
2004 Mayhew CN, Bosco EE, Solomon DA, Knudsen ES, Angus SP. Analysis of RB action in DNA damage checkpoint response. Methods in Molecular Biology (Clifton, N.J.). 281: 3-16. PMID 15220518 DOI: 10.1385/1-59259-811-0:003  0.63
2004 Angus SP, Mayhew CN, Solomon DA, Braden WA, Markey MP, Okuno Y, Cardoso MC, Gilbert DM, Knudsen ES. RB reversibly inhibits DNA replication via two temporally distinct mechanisms. Molecular and Cellular Biology. 24: 5404-20. PMID 15169903 DOI: 10.1128/Mcb.24.12.5404-5420.2004  0.663
2004 Gunawardena RW, Siddiqui H, Solomon DA, Mayhew CN, Held J, Angus SP, Knudsen ES. Hierarchical requirement of SWI/SNF in retinoblastoma tumor suppressor-mediated repression of Plk1. The Journal of Biological Chemistry. 279: 29278-85. PMID 15105433 DOI: 10.1074/Jbc.M400395200  0.749
2003 Angus SP, Solomon DA, Kuschel L, Hennigan RF, Knudsen ES. Retinoblastoma Tumor Suppressor: Analyses of Dynamic Behavior in Living Cells Reveal Multiple Modes of Regulation Molecular and Cellular Biology. 23: 8172-8188. PMID 14585976 DOI: 10.1128/Mcb.23.22.8172-8188.2003  0.652
2003 Knudsen ES, Angus SP. Functional analysis of the antimitogenic activity of tumor suppressors. Methods in Molecular Biology (Clifton, N.J.). 218: 3-15. PMID 12616708 DOI: 10.1385/1-59259-356-9:03  0.636
2002 Markey MP, Angus SP, Strobeck MW, Williams SL, Gunawardena RW, Aronow BJ, Knudsen ES. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Research. 62: 6587-97. PMID 12438254  0.741
2002 Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. The Journal of Biological Chemistry. 277: 44376-84. PMID 12221087 DOI: 10.1074/Jbc.M205911200  0.701
2002 Angus SP, Fribourg AF, Markey MP, Williams SL, Horn HF, DeGregori J, Kowalik TF, Fukasawa K, Knudsen ES. Active RB elicits late G1/S inhibition. Experimental Cell Research. 276: 201-13. PMID 12027450 DOI: 10.1006/Excr.2002.5510  0.662
2002 Strobeck MW, Reisman DN, Gunawardena RW, Betz BL, Angus SP, Knudsen KE, Kowalik TF, Weissman BE, Knudsen ES. Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. The Journal of Biological Chemistry. 277: 4782-9. PMID 11719516 DOI: 10.1074/Jbc.M109532200  0.713
2001 Angus SP, Edelmann RE, Pennock DG. Targeted gene knockout of inner arm 1 in Tetrahymena thermophila. European Journal of Cell Biology. 80: 486-97. PMID 11499791 DOI: 10.1078/0171-9335-00178  0.327
2001 Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE, Knudsen ES. Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Molecular and Cellular Biology. 21: 4032-45. PMID 11359910 DOI: 10.1128/Mcb.21.12.4032-4045.2001  0.677
1999 Xu W, Royalty MP, Zimmerman JR, Angus SP, Pennock DG. The dynein heavy chain gene family in Tetrahymena thermophila. The Journal of Eukaryotic Microbiology. 46: 606-11. PMID 10568033 DOI: 10.1111/J.1550-7408.1999.Tb05136.X  0.318
Show low-probability matches.